Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Moleculin Biotech CS (MBRX)

Moleculin Biotech CS (MBRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 42,010
  • Shares Outstanding, K 28,578
  • Annual Sales, $ 0 K
  • Annual Income, $ -15,890 K
  • 60-Month Beta 1.79
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.57
Trade MBRX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.25
  • Number of Estimates 2
  • High Estimate -0.25
  • Low Estimate -0.25
  • Prior Year -0.19
  • Growth Rate Est. (year over year) -31.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2600 +16.67%
on 06/16/22
1.5500 -5.16%
on 06/08/22
-0.0400 (-2.65%)
since 06/01/22
3-Month
1.0200 +44.12%
on 05/12/22
2.0500 -28.29%
on 04/14/22
-0.3500 (-19.23%)
since 04/01/22
52-Week
1.0200 +44.12%
on 05/12/22
3.7400 -60.70%
on 07/13/21
-2.1200 (-59.05%)
since 07/01/21

Most Recent Stories

More News
Moleculin Announces Completion of First Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug...

MBRX : 1.4700 (+1.38%)
JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th

- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast presentations of participating companies followed by interactive Q&A session - PITTSTOWN, NJ / ACCESSWIRE...

CZO.VN : 0.590 (-1.67%)
CRPOF : 0.4550 (-3.15%)
VLON : 0.6200 (-3.08%)
XBIO : 0.7600 (-5.13%)
NVNO : 3.87 (+2.38%)
CRBP : 0.2583 (+2.42%)
OTLK : 1.0200 (unch)
AEZS : 0.2161 (+9.81%)
AEZS.TO : 0.2600 (-21.21%)
AIM : 0.7810 (+0.13%)
CNSP : 0.2650 (-5.36%)
MBRX : 1.4700 (+1.38%)
JTC Team to Host Virtual Investor Roundtable Event on November 16th, 17th, and 18th

- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast roundtable discussions with members of Management and Thought Leaders across participating companies...

CZO.VN : 0.590 (-1.67%)
CRPOF : 0.4550 (-3.15%)
OTLK : 1.0200 (unch)
CYTH : 2.02 (+2.54%)
NVNO : 3.87 (+2.38%)
SING : 0.0740 (unch)
AREC : 1.5100 (+4.14%)
NOVN : 2.30 (-1.29%)
CNSP : 0.2650 (-5.36%)
MBRX : 1.4700 (+1.38%)
VLON : 0.6200 (-3.08%)
Moleculin Receives Authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) to Commence Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug...

MBRX : 1.4700 (+1.38%)
WPD Pharmaceuticals to Receive $6.7 Million Grant for Development of Annamycin Drug Candidate

VANCOUVER, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “ Company ” or “ WPD ”) a clinical-stage pharmaceutical company, is pleased...

WBIO.CN : 0.045 (unch)
MBRX : 1.4700 (+1.38%)
WPD Pharmaceuticals’ Licensor Announces 100% Survival Achieved in Osteosarcoma Lung Metastases Animal Model of Annamycin Drug

Potentially significant therapeutic benefit against metastatic, Annamycin shown to reach "sanctuary sites" of cancer

WBIO.CN : 0.045 (unch)
MBRX : 1.4700 (+1.38%)
Global Sarcoma Drugs Market Size Could Reach $1.2 Billion By 2023

Palm Beach, FL – December 17, 2020 – Soft tissue sarcoma (STS) is a rare type of cancer that develops in tissues such as nerves, muscles, fats, blood vessels and deep skin tissues. Generally occurring...

MNKD : 3.98 (+4.46%)
MBRX : 1.4700 (+1.38%)
CRDF : 2.33 (+5.91%)
RIGL : 1.2500 (+10.62%)
AZN : 65.95 (-0.18%)
Moleculin Announces FDA Permission to Begin Clinical Study of Annamycin for Sarcoma Lung Metastases

Houston, TX –  December 17, 2020 – Moleculin Biotech, Inc., (NASDAQ: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting...

MBRX : 1.4700 (+1.38%)
Development of Advanced Novel AML Drugs Target Increasing Cases of Acute Myeloid Leukemia

Palm Beach, FL – December 3, 2020 – Acute myeloid leukemia (AML) is a rare and heterogeneous blood cancer with a poor overall prognosis. It affects predominantly older adults with a median age at diagnosis...

MBRX : 1.4700 (+1.38%)
IBIO : 0.2600 (-1.52%)
MACK : 5.83 (-2.02%)
CATB : 8.54 (-6.97%)
AZN : 65.95 (-0.18%)
Moleculin To Present Antitumor Activity of Annamycin in Combination with Ara-C in AML at American Society for Hematology Annual Conference

Houston, TX – December 3, 2020 – Moleculin Biotech, Inc. , (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly...

MBRX : 1.4700 (+1.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company which focused on the development of anti-cancer drug candidates. The company's lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia....

See More

Key Turning Points

3rd Resistance Point 1.6367
2nd Resistance Point 1.5833
1st Resistance Point 1.5267
Last Price 1.4700
1st Support Level 1.4167
2nd Support Level 1.3633
3rd Support Level 1.3067

See More

52-Week High 3.7400
Fibonacci 61.8% 2.7010
Fibonacci 50% 2.3800
Fibonacci 38.2% 2.0590
Last Price 1.4700
52-Week Low 1.0200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar